Clinical trials: Demyelinating Disorder
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Adults with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) who have completed study 161403 will be able to take part in this study.
- Trial name
- NCT02955355
- Testing
- HYQVIA
- Where
- 35 sites in United States, Argentina and 16 more
- Volunteers
- 85 people
- Sponsor
- Baxalta now part of Shire
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Relapsing Multiple Scelrosis
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.
To compare the efficacy and safety of ofatumumab administered subcutaneously (sc) every 4 weeks versus teriflunomide administered orally once daily in patients with relapsing multiple sclerosis
- Trial name
- ASCLEPIOS II (NCT02792231)
- Testing
- Ofatumumab subcutaneous injection, Teriflunomide capsule
- Where
- 178 sites in United States, Argentina and 28 more
- Volunteers
- 955 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
PF-06342674 (RN168), being developed for the treatment of multiple sclerosis (MS), is an antibody that binds to and inhibits the human interleukin-7 receptor, a component potentially involved in MS.
- Trial name
- NCT02045732
- Testing
- PF-06342674 0.25 mg/kg, PF-06342674 1.5 mg/kg, PF-06342674 6.0 mg/kg
- Where
- 8 sites in United States
- Volunteers
- 4 people
- Sponsor
- Pfizer
Lysosomal Storage Disease, Peroxisomal Disorder
Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders
This study is designed to test the ability to achieve donor hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM) in patients with high-risk lysosomal and peroxisomal disorders using a novel…
- Trial name
- NCT01626092
- Testing
- Campath-1H, Clofarabine, Melphalan
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Neuromyelitis Optica, Devic's Disease
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
The purpose of this study is to determine if the drug eculizumab reduces the attack rate and improves outcome in patients with neuromyelitis optica.
- Trial name
- NCT00904826
- Testing
- Eculizumab
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Mayo Clinic
Chronic Pain, Brain Injuries, Traumatic
Telehealth Pain Self-Management for Employed Adults
The E-TIPS trial will evaluate an evidence-based, telehealth pain self-management intervention compared to standard care (a waitlist) for chronic pain in adults with physical disabilities who are employed.
- Conditions
- Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries
- Trial name
- E-TIPS (NCT04248725)
- Testing
- E-TIPS
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Washington
Multiple Sclerosis
A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis
This was a Phase 2, randomized, double-blind, placebo-controlled 2 parallel-arm study to assess the effect on serum neurofilament light chain (sNfL), safety and tolerability of oral SAR443820 compared to placebo in male and…
- Trial name
- NCT05630547
- Testing
- SAR443820
- Where
- 35 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Sanofi
Multiple Sclerosis, Back Pain
A Pilot Project for Multifidus Muscle Evaluation in Patients With Multiple Sclerosis
This research study plans to evaluate if multifidus muscle dysfunction is associated with back pain in patients with Multiple Sclerosis (MS).
- Trial name
- NCT05427045
- Testing
- home - exercise program
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Arkansas
Multiple Sclerosis
Telehealth-Based Exercise Program to Treat Fatigue in MS
This is a clinical trial examining a brief motivational intervention to improve adherence to exercise among individuals with MS to improve fatigue.
- Trial name
- MS-FIT (NCT01198977)
- Testing
- Brief telephone-based counseling, Education counseling
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Idebenone for Primary Progressive Multiple Sclerosis
Background: The Idebenone in Patients With Primary Progressive Multiple Sclerosis (IPPoMS) trial tested a new drug for multiple sclerosis. In the IPPoMS trial, participants took either idebenone or placebo.
- Trial name
- NCT01854359
- Testing
- Idebenone
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis, Relapsing-remitting
Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health
This is a pilot study of oral vitamin D supplementation to determine if patients with Multiple Sclerosis (MS) and healthy individuals attain a similar increase in serum 25-hydroxyvitamin D levels.
- Trial name
- NCT01667796
- Testing
- Vitamin D3
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Spasticity
Developing and Testing a Comprehensive MS Spasticity Management Program
This is a study to determine the impact of education and specific lower extremity stretches for MS-related spasticity. The study will evaluate the acceptance and efficacy of education and stretching using a randomized controlled…
- Trial name
- NCT02170779
- Testing
- Spasticity: Take Control, Usual care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- VA Office of Research and Development
Multiple Sclerosis, Pain
Usability of the MeTime MS App
The Me Time MS Application was designed to enable self-administration of acupressure. Two forms of acupressure - either "relaxing" or "stimulating" protocols - are administered through the Me Time MS app.
- Conditions
- Multiple Sclerosis, Pain, Fatigue Symptom
- Trial name
- NCT07123272
- Testing
- Self-guided smartphone application for relaxing acupressure, Self-guided smartphone application for stimulating acupressure
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Michigan
Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)
The objective of this study is to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic, and immunogenic profiles of satralizumab, compared with placebo, in addition to baseline immunosuppressive treatment in…
- Trial name
- NCT02028884
- Testing
- Satralizumab, Baseline Treatment
- Where
- 40 sites in United States, France and 9 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Progressive Multiple Sclerosis
A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis
This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS).
- Trial name
- NCT03423121
- Testing
- Tauroursodeoxycholic Acid
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis
The main purpose of this study is to assess clemastine as a remyelinating agent in patients with relapsing forms of multiple sclerosis.
- Trial name
- ReBUILD (NCT02040298)
- Testing
- Clemastine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Francisco
Relapsing Remitting Multiple Sclerosis
Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab
The primary objective of this study is to assess the efficacy of Ocrelizumab (OCR) in Relapsing Multiple Sclerosis patients who have been previously treated with natalizumab (NTZ) by evaluating relapse rate, progression on MRI…
- Trial name
- OCTAVE (NCT03157830)
- Where
- 5 sites in United States
- Volunteers
- 43 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Relapsing-Remitting
Establish Tolerance In MS With Peptide-Coupled, Peripheral Blood Mononuclear Cells
Open-label, single center, phase I clinical trial to assess the safety, tolerability and preliminary efficacy and in vivo mechanisms of action of i.v.
- Trial name
- ETIMS (NCT01414634)
- Testing
- ETIMS
- Volunteers
- 9 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Multiple Sclerosis
Locomotor Training in Persons With Multiple Sclerosis
Locomotor training is a new exercise modality that emphasizes task specificity to promote learning and neural plasticity. It has been reported to improve walking in patients with stroke, spinal cord injury and cerebral palsy.
- Trial name
- NCT00607126
- Testing
- Lokomat, resistive training
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, Los Angeles